What Happened? Shares of pharmaceutical company Organon (NYSE:OGN) fell 8.9% in the afternoon session after the company ...

Organon (OGN) shares have drifted lower over the past month, reflecting a slide of more than 34% even as the broader healthcare sector remains in focus. Investors continue to monitor recent ...

Organon (NYSE:OGN) shares fell 18% on Monday after the company announced that CEO Kevin Ali has resigned following the ...

Investing.com -- Organon (NYSE:OGN) stock plunged 18% after the company announced CEO Kevin Ali’s resignation following an internal investigation that uncovered improper wholesaler sales practices for ...

Organon stock plunged after CEO's exit and audit probe. Discover if its low valuation, global portfolio, and earnings ...

If you’re standing at the crossroads wondering what to do with Organon stock, you’re not alone. Lately, it seems every time Organon gets mentioned, investors are weighing their options just as ...

According to the press release and the results from the investigation so far, Organon will likely not have to restate any of ...

Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

We recently published 11 Stocks Jim Cramer Discussed, Including A Potential “Worst Stock Ever”. Organon & Co. (NYSE:OGN) is ...

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

While he has resigned, rather than being sacked, Ali has agreed to leave his post without being entitled to any severance ...

Organon announced that CEO Kevin Ali intends to resign from his position following results from an internal investigation ...